Just over a year after partnering on a project to accelerate recruitment into decentralised clinical trials (DCTs), Thread and CureClick have decided to formally tie the knot.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh